Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results CC transcript Director departure Inv. presentation Appointed director
|
Stereotaxis, Inc. (STXS)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/10/2023 |
8-K
| Quarterly results |
05/09/2023 |
8-K
| Quarterly results |
03/03/2023 |
8-K
| Quarterly results |
11/10/2022 |
8-K
| Quarterly results |
08/09/2022 |
8-K
| Quarterly results |
05/10/2022 |
8-K
| Quarterly results |
03/03/2022 |
8-K
| Quarterly results |
11/12/2021 |
8-K
| Quarterly results |
05/10/2021 |
8-K
| Quarterly results |
02/25/2021 |
8-K
| Quarterly results |
11/09/2020 |
8-K
| Quarterly results |
08/06/2020 |
8-K
| Quarterly results |
05/05/2020 |
8-K
| Quarterly results |
03/10/2020 |
8-K
| Quarterly results |
11/14/2019 |
8-K
| Quarterly results |
08/08/2019 |
8-K
| Quarterly results |
05/09/2019 |
8-K
| Quarterly results
Docs:
|
"Stereotaxis Reports 2019 First Quarter Financial & Operational Results ST. LOUIS, MO, May 9, 2019 – Stereotaxis , the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2019. In separate press releases issued concurrently with this release, Stereotaxis showcased for the first time a next-generation robotic system, a novel x-ray imaging system, and a development program for a proprietary robotically-navigated magnetic ablation catheter. “The start of 2019 is highlighted by significant innovation accomplishments across all key aspects of our technology,” said David Fischel, Chairman and CEO. “These innovations will positively impact patient care, the physician experience, and the br..." |
|
03/12/2019 |
8-K
| Quarterly results |
11/13/2018 |
8-K
| Quarterly results
Docs:
|
"Stereotaxis Reports 2018 Third Quarter Financial Results ● Continued progress on strategic innovation initiatives; expect to showcase in 1H 2019 ● 4% recurring revenue growth; reaffirming 2018 record recurring revenue expectations ● Conference call today at 10:00 a.m. Eastern Time ST. LOUIS, MO, Nov. 12, 2018 – Stereotaxis, Inc. , the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2018. “We continue to make meaningful progress on our strategic innovation initiatives, and expect to be able to publicly showcase our progress in the first half of 2019,” said David Fischel, Chairman and CEO. “We are confident that our innovation strategy is clinically and comm..." |
|
08/07/2018 |
8-K
| Quarterly results |
05/14/2018 |
8-K
| Quarterly results |
03/06/2018 |
8-K
| Quarterly results |
11/09/2017 |
8-K
| Quarterly results |
08/10/2017 |
8-K
| Quarterly results |
05/08/2017 |
8-K
| Form 8-K - Current report |
11/07/2016 |
8-K
| Quarterly results |
08/09/2016 |
8-K
| Form 8-K - Current report |
05/09/2016 |
8-K
| Form 8-K - Current report |
02/22/2016 |
8-K
| Quarterly results |
11/03/2015 |
8-K
| Quarterly results |
08/04/2015 |
8-K
| Quarterly results |
05/06/2015 |
8-K
| Quarterly results |
02/25/2015 |
8-K
| Quarterly results |
11/06/2014 |
8-K
| Quarterly results, Conference call transcript |
|
|
|